Aclarion Added to PRISM Emerging Medical Devices Index
07 9월 2024 - 12:27AM
PRISM MarketView, a leading provider of market insights and company
news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has
been added to the PRISM Emerging Medical Devices Index, which
highlights companies at the forefront of innovation and market
disruption in the medtech sector. Aclarion’s innovative AI-driven
diagnostic solutions for chronic low back pain position the company
as a standout in the evolving medical devices sector.
The U.S. medical devices market is projected to grow
significantly, reaching an estimated value of nearly $315 billion
by 2032. This expansion is driven by increasing R&D investments
and a robust pipeline of innovations, including Aclarion’s NOCISCAN
technology, which offers the first noninvasive, AI-supported
diagnostic tool for identifying painful discs in patients suffering
from chronic low back pain.
Lower back pain is one of the largest healthcare expenditures in
the United States, with the market for lumbar spine diagnostics and
treatment estimated at $40 billion annually and overall costs
reaching up to $134.5 billion. Aclarion’s NOCISCAN technology
addresses this growing need by offering a noninvasive diagnostic
alternative.
Aclarion Standouts:
- Industry-First Noninvasive Diagnostic:
Aclarion’s NOCISCAN technology is the first of its kind, providing
a noninvasive alternative to traditional diagnostics and delivering
improved surgical outcomes for patients with lower back pain.
- Strong Market Validation: Aclarion is
addressing one of the world’s largest and most costly health
challenges—degenerative spine diseases and lower back pain,
affecting 266 million patients globally. The company’s proven
technology, along with newly established regulatory pathways and
payer coverage, is paving the way for broader global adoption and
driving strong market validation.
- Partnerships and Agreements: Aclarion secured
its first commercial agreement in Michigan with Sheridan Community
Hospital, bringing NOCISCAN to central Michigan. In addition, the
company extended its commercial agreement with The London Clinic,
increasing access throughout the London market. Aclarion has also
secured private payer coverage from major UK insurers, including
AXA, Aviva and Vitality, providing access to 60% of private health
insurance patients in greater London. Yesterday, the company
announced the launch of a program to develop a statewide network of
providers in New Jersey to utilize NOCISCAN throughout the personal
injury and workers' compensation population.
- Clinical Evidence: Aclarion’s technology is
supported by strong clinical data, demonstrating an 85% improvement
in patients treated based on NOCISCAN diagnostics. Several clinical
trials are currently underway, including the CLARITY trial, which
is set to enroll up to 300 patients. Patient enrollment is expected
to begin in Q4 2024, with interim data available by Q1 2026 and
full data by Q2 2026. The company is actively conducting additional
trials to further validate the efficacy of its technology.
For more information on Aclarion and the PRISM Emerging Medical
Devices Index, visit prismmarketview.com.
About Aclarion, Inc.Aclarion is a healthcare
technology company that leverages magnetic resonance spectroscopy
(“MRS”), proprietary signal processing techniques, biomarkers and
augmented intelligence algorithms to optimize clinical treatments.
The Company is first addressing the chronic low back pain market
with NOCISCAN, the first, evidence-supported SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Through a cloud connection,
NOCISCAN receives magnetic resonance spectroscopy data from an MRI
machine for each lumbar disc being evaluated. In the cloud,
proprietary signal processing techniques extract and quantify
chemical biomarkers demonstrated to be associated with disc pain.
Biomarker data is entered into proprietary algorithms to indicate
if a disc may be a source of pain. When used with other diagnostic
tools, NOCISCAN provides critical insights into the location of a
patient’s low back pain, giving physicians clarity to optimize
treatment strategies. For more information, please
visit www.aclarion.com.
About PRISM MarketView Established in
2020, PRISM MarketView is dedicated to the monitoring and analysis
of small cap stocks in burgeoning sectors. We deliver
up-to-the-minute financial market news, provide comprehensive
investor tools and foster a dynamic investor community. Central to
our offerings are proprietary indexes that observe emerging
sectors, including biotech, clean energy, next-generation tech,
medical devices and beyond. Visit us
at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.
Disclaimer: This communication was produced by
PRISM MarketView, an affiliate of PCG Advisory Inc., (together
"PCG"). PCG is not a registered or licensed broker-dealer nor
investment adviser. No information contained in this communication
constitutes an offer to sell, a solicitation of an offer to buy, or
a recommendation of any security. PCG may be compensated by
respective clients for publicizing information relating to its
clients’ securities. See www.pcgadvisory.com/disclosures.
Contact:
PRISM
MarketView
info@prismmarketview.com
646-863-6341
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a4c45b4-63ec-4049-a7b8-16369cff9c9a
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024